Discussion and case analysis of clinical development strategy of small-molecule targeted anti-cancer drugs

Chinese Journal of New Drugs

Volumn 22, Issue 3, 2013, Pages 269-273

  Chen, Xiao Yuan ^a   Zhang, Hong ^a   Gao, Chen Yan ^a   Yang, Zhi Min ^a  

^a CENTER FOR DRUG EVALUATION   (China)

Author keywords

Clinical study; Critizonib; Gefitinib; Icotinib; Small molecule targeted anti cancer drug

Indexed keywords

ANTINEOPLASTIC AGENT; CRITIZONIB; GEFITINIB; ICOTINIB; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL DEVELOPMENT PLAN; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; MOLECULARLY TARGETED THERAPY;

EID: 84881274136     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Trinh Pham, Pharm D. The latest FDA drug approvals: what you need to know[J]. Drug Topics, 2012, (3): 62-71.
2. SODA M, CHOI Y L, ENOMOTO M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
3. KWAK E L, BAND Y J, CAMIDGE D R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer[J]. N Engl J Med, 2010, 363(18): 1693-1703.
4. 2011, 20(17): 1615-1619.